ARamachol™ for REsolution of STeatohepatitis (ARREST)
400mg; 600mg; Placebo
Once‐daily tablet for 12 months and 3 months follow‐up
No. of Subjects
- Percent change in the liver triglycerides concentration measured by MRS
- Proportion in percentages of subjects with NASH Resolution — ballooning 0; inflammation 0 or 1 — without worsening of CRN Fibrosis Score
- Proportion in percentages of subjects with CRN Fribrosis Score Improvement without worsening of NASHProportion in percentages of subjects with CRN Fribrosis Score Improvement without worsening of NASH
These results were presented during a Late Breaking Abstract Oral Session at The Liver Meeting® 2018 during the American Association for the Study of Liver Diseases (AASLD).